In a nutshell This study investigated the vascular (blood vessels) side effects associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML). This study concluded that patients treated with nilotinib (Tasigna) experienced more vascular side effects. Some background Tyrosine kinase (TK) inhibitors are the standard therapy...
Read More
In a nutshell This study aimed to investigate outcomes of salvage therapy after treatment with fludarabine, cyclophosphamidine and rituximab fails in patients with chronic lymphocytic leukemia. This study concluded that salvage therapy can provide excellent outcomes for these patients. Some background Fludarabine (Fludara) is a chemotherapy used...
Read More
In a nutshell This study compared the effectiveness of nilotinib (Tasigna) with high-dose imatinib (Glivec) in patients with unresponsive chronic myeloid leukemia. Researchers concluded that nilotinib may be more effective as a long-term treatment for CML when compared to imatinib. Some background Chronic myeloid leukemia is a cancer of the bone...
Read More
When I think of vaccines, I think of the MMRV (measles, mumps, rubella and varicella) vaccines which help our bodies establish immunity against diseases that used to kill. Now, there are vaccines being created for cancer. The rise of cancer vaccines According to Dr. Nora Disis, an oncologist and researcher in cancer vaccines at the University of...
Read More
In a nutshell This study aimed to investigate the benefits of monitoring early molecular response markers for chronic myeloid leukemia. This study concluded that monitoring BCR-ABL1 values at an early stage could help with assessing response and making decisions regarding timing of treatments. Some background Measuring molecular response markers...
Read MoreIn a nutshell This study examined the major factors associated with disease progression and outcomes in adults with acute myeloid leukemia (AML). The authors found that younger age, less molecular mutations and choice of induction therapy were all positively associated with higher rates of complete remission and survival. Some background A number...
Read More
In a nutshell This study aimed to identify the outcomes and prognostic factors following a stem cell transplant from a donor in adults with acute myeloid leukemia in their second complete remission (no sign of disease). The authors determined that this type of transplant was effective in these patients. Some background In adult patients with acute...
Read MoreIn a nutshell This study aimed to investigate the safety of obinutuzumab (Gazyva) in a range of patients with chronic lymphocytic leukemia. This study concluded that obinutuzumab is safe and tolerable for a range of patients with chronic lymphocytic leukemia. Some background Obinutuzumab is a targeted therapy for chronic lymphocytic...
Read More
In a nutshell This study aimed to assess treatment plans and outcomes in children with acute lymphoblastic leukemia and genetic abnormalities in the Philadelphia chromosome (Ph-positive). The study concluded that adding imatinib (Gleevec) to intensive chemotherapy may be an effective treatment for these patients. Some background Acute lymphoblastic...
Read More
In a nutshell This study aimed to identify risk factors leading to a longer hospital stay in children being treated with chemotherapy for high-risk acute lymphoblastic leukemia (ALL). The study found that a high amount of young patients treated for high-risk ALL experienced a longer hospital stay. Some background Acute lymphoblastic leukemia...
Read More
In a nutshell This study looked at the safety and effectiveness of blinatumomab (Blincyto) compared with standard chemotherapy in the treatment of acute lymphoblastic leukemia (ALL). The study found that blinatumomab was a safe and effective treatment option compared to chemotherapy in patients with ALL. Some background Acute lymphoblastic leukemia is...
Read More
In a nutshell This study aimed to investigate the effectiveness of nilotinib (Tasigna) as a consolidation therapy for chronic myeloid leukemia patients. This study concluded that nilotinib is safe and effective as a consolidation therapy in these patients. Some background Nilotinib is a targeted therapy used to treat chronic myeloid leukemia...
Read More
